PTEN and melanomagenesis

Future Oncology

Volumn 8, Issue 9, 2012, Pages 1109-1120

  Conde Perez, Alejandro ^a,b   Larue, Lionel ^a,b  

^a INSTITUT CURIE   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

catenin; LOH; MAPK; melanoblasts; PI3K

Indexed keywords

B RAF KINASE; BETA CATENIN; DABRAFENIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR FOXO; VEMURAFENIB;

CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; GENE CONTROL; HETEROZYGOSITY LOSS; MELANOMA; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; ANIMALS; CATALYTIC DOMAIN; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MELANOCYTES; MELANOMA; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84867072914     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.106     Document Type: Review

References (113)

1. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104(13), 5569-5574 (2007).
2. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).
3. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63(11), 2881-2890 (2003).
4. Elder DE, Guerry DT, Epstein MN et al. Invasive malignant melanomas lacking competence for metastasis. Am. J. Dermatopathol. 6(Suppl. 1), 55-61 (1984).
5. Herlyn M, Thurin J, Balaban G et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 45(11 Pt 2), 5670-5676 (1985).
6. Larue L, Beermann F. Cutaneous melanoma in genetically modified animals. Pigment Cell Res. 20(6), 485-497 (2007).
7. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J. Clin. 35(3), 130-151 (1985).
8. Aldridge RB, Zanotto M, Ballerini L, Fisher RB, Rees JL. Novice identification of melanoma: not quite as straightforward as the ABCDs. Acta Derm. Venereol. 91(2), 125-130 (2011).
9. Salerni G, Lovatto L, Carrera C, Puig S, Malvehy J. Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. Arch. Dermatol. 147(5), 549-555 (2011).
10. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J. Clin. 60(5), 301-316 (2010).
11. Shenenberger DW. Cutaneous malignant melanoma: a primary care perspective. Am. Fam. Physician 85(2), 161-168 (2012).
12. Djordjevic B, Hennessy BT, Li J et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod. Pathol. 25, 699-708 (2012).
13. Paraiso KH, Xiang Y, Rebecca VW et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71(7), 2750-2760 (2011).
14. Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140(2), 209-221 (2010).
15. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085-3096 (2011).
16. Greger JG, Eastman SD, Zhang V et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11(4), 909-920 (2012).
17. Martí RM, Sorolla A, Yeramian A. New therapeutic targets in melanoma. Actas Dermosifiliogr. 103(7), 579-590 (2012).
18. Robert C, Mateus C. Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma. Med. Sci. (Paris) 27(10), 850-858 (2011).
19. Yang Z, Lei Z, Li B et al. Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci. 101(2), 494-500 (2010).
20. Espona-Fiedler M, Soto-Cerrato V, Hosseini A et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem. Pharmacol. 83(4), 489-496 (2012).
21. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2, 248-258 (2012).
22. Atefi M, Von Euw E, Attar N et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/ mTOR pathway. PLoS ONE 6(12), e28973 (2011)
23. Boniol M, Armstrong BK, Doré JF. Variation in incidence and fatality of melanoma by season of diagnosis in New South Wales, Australia. Cancer Epidemiol. Biomarkers Prev. 15(3), 524-526 (2006).
24. Mcpherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J. Am. Acad. Dermatol. 54(5), 783-792 (2006).
25. Tournillac I, Picot MC, Dereure O, Guilhou JJ, Guillot B. [Dubreuilh melanoma: and epidemiologic and prognostic study]. Ann. Dermatol. Venereol. 126(10), 676-680 (1999).
26. Saxe N, Hoffman M, Krige JE, Sayed R, King HS, Hounsell K. Malignant melanoma in Cape Town, South Africa. Br. J. Dermatol. 138(6), 998-1002 (1998).
27. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83(8), 1664-1678 (1998).
28. Moloney FJ, Menzies SW. Key points in the dermoscopic diagnosis of hypomelanotic melanoma and nodular melanoma. J. Dermatol. 38(1), 10-15 (2011).
29. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29(3), 705-727 (1969).
30. Situm M, Bolanca Z, Buljan M. Lentigo maligna melanoma-the review. Coll. Antropol. 34(Suppl. 2), 299-301 (2010).
31. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch. Dermatol. 145(4), 427-434 (2009).
32. Swan MC, Hudson DA. Malignant melanoma in South Africans of mixed ancestry: a retrospective analysis. Melanoma Res. 13(4), 415-419 (2003).
33. Bellows CF, Belafsky P, Fortgang IS, Beech DJ. Melanoma in African-Americans: trends in biological behavior and clinical characteristics over two decades. J. Surg. Oncol. 78(1), 10-16 (2001).t
34. Miranda BH, Haughton DN, Fahmy FS. Subungual melanoma: an important tip. J. Plast. Reconstr. Aesthet. Surg. doi:10.1016/j. bjps.2012.03.001 (2012) (Epub ahead of print).
35. Piliang MP. Acral lentiginous melanoma. Clin. Lab. Med. 31(2), 281-288 (2011).
36. Bastian BC, Kashani-Sabet M, Hamm H et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60(7), 1968-1973 (2000).
37. Delmas V, Beermann F, Martinozzi S et al. Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 21(22), 2923-2935 (2007).
38. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/ MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60(7), 1800-1804 (2000).
39. Hayward NK. Genetics of melanoma predisposition. Oncogene 22(20), 3053-3062 (2003).
40. Ackermann J, Frutschi M, Kaloulis K, Mckee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65(10), 4005-4011 (2005).
41. Gray-Schopfer VC, Cheong SC, Chong H et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95(4), 496-505 (2006).
42. Halaban R. Growth factors and melanomas. Semin. Oncol. 23(6), 673-681 (1996).
43. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6(4), 313-319 (2004).
44. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051), 720-724 (2005).
45. Chin L, Tam A, Pomerantz J et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400(6743), 468-472 (1999).
46. Ha L, Merlino G, Sviderskaya EV. Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle 7(13), 1944-1948 (2008).
47. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308), 1943-1947 (1997).
48. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q233 that is mutated in multiple advanced cancers. Nat. Genet. 15(4), 356-362 (1997).
49. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp. Cell Res. 264(1), 29-41 (2001).
50. Lee JO, Yang H, Georgescu MM et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99(3), 323-334 (1999).
51. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc. Natl Acad. Sci. USA 106(2), 480-485 (2009).
52. Wu X, Hepner K, Castelino-Prabhu S et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl Acad. Sci. USA 97(8), 4233-4238 (2000).
53. Knobbe CB, Lapin V, Suzuki A, Mak TW. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27(41), 5398-5415 (2008).
54. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005).
55. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280(49), 40406-40416 (2005).
56. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 133(3), 403-414 (2008).
57. Aguissa-Toure AH, Li G. Genetic alterations of PTEN in human melanoma. Cell. Mol. Life Sci. 69(9), 1475-1491 (2012).
58. Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer. 99(1), 63-67 (2002).
59. Zhou XP, Loukola A, Salovaara R et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol. 161(2), 439-447 (2002).
60. Perren A, Komminoth P, Saremaslani P et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared with normal islet cells. Am. J. Pathol. 157(4), 1097-1103 (2000).
61. Fridberg M, Servin A, Anagnostaki L et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk. Lymphoma 48(11), 2221-2232 (2007).
62. Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J. Cell Sci. 121(Pt 3), 249-253 (2008).
63. Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum. Mol. Genet. 15(17), 2553-2559 (2006).
64. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1), 157-170 (2007).
65. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 3(2), 117-130 (2003).
66. Chen Z, Trotman LC, Shaffer D et al. Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature 436(7051), 725-730 (2005).
67. Song MS, Carracedo A, Salmena L et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell 144(2), 187-199 (2011).
68. Garcia-Cao I, Song MS, Hobbs RM et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149(1), 49-62 (2012).
69. Okumura K, Mendoza M, Bachoo RM, Depinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J. Biol. Chem. 281(36), 26562-26568 (2006).
70. Kwon J, Lee SR, Yang KS et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl Acad. Sci. USA 101(47), 16419-16424 (2004).
71. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI3-kinase signalling via inactivation of PTEN. EMBO J. 22(20), 5501-5510 (2003).
72. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277(23), 20336-20342 (2002).
73. Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE. Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1 Cell Cycle 4(10), 1389-1395 (2005).
74. Trotman LC, Wang X, Alimonti A et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128(1), 141-156 (2007).
75. Wang X, Trotman LC, Koppie T et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128(1), 129-139 (2007).
76. Fouladkou F, Landry T, Kawabe H et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl Acad. Sci. USA 105(25), 8585-8590 (2008).
77. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A codingindependent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465(7301), 1033-1038 (2010).
78. Berger MF, Hodis E, Heffernan TP et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399), 502-506 (2012).
79. Miller SJ, Lou DY, Seldin DC, Lane WS, Nee LBG. Direct identification of PTEN phosphorylation sites. FEBS Lett. 528(1-3), 145-153 (2002).
80. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus: implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276(2), 993-998 (2001).
81. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 280(42), 35195-35202 (2005).
82. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum. Mutat. 16(2), 109-122 (2000).
83. Farooq A, Walker LJ, Bowling J, Audisio RA. Cowden syndrome. Cancer Treat. Rev. 36(8), 577-583 (2010).
84. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16(1), 64-67 (1997).
85. Yang MS, Kim CH, Cheong JH, Kim JM. Lhermitte-Duclos disease presenting with hydrocephalus. Acta. Neurochir. Suppl. 113, 161-165 (2012).
86. Tok Celebi J, Chen FF, Zhang H, Ping XL, Tsou HC, Peacocke M. Identification of PTEN mutations in five families with Bannayan-Zonana syndrome. Exp. Dermatol. 8(2), 134-139 (1999).
87. Virchow RLK. Cellular Pathology. John Churchill, London, UK (1859).
88. Grille SJ, Bellacosa A, Upson J et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63(9), 2172-2178 (2003).
89. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer. role of phosphatidylinositol 3́ kinase/AKT pathways. Oncogene 24(50), 7443-7454 (2005).
90. Kim D, Kim S, Koh H et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15(11), 1953-1962 (2001).
91. Henle SJ, Wang G, Liang E, Wu M, Poo MM, Henley JR. Asymmetric PI(3,4,5)P3 and Akt signaling mediates chemotaxis of axonal growth cones. J. Neurosci. 31(19), 7016-7027 (2011).
92. Puig I, Champeval D, De Santa Barbara P, Jaubert F, Lyonnet S, Larue L. Deletion of PTEN in the mouse enteric nervous system induces ganglioneuromatosis and mimics intestinal pseudoobstruction. J. Clin. Invest. 119(12), 3586-3596 (2009).
93. Colombo S, Champeval D, Rambow F, Larue L. Transcriptomic analysis of mouse embryonic skin cells reveals previously unreported genes expressed in melanoblasts. J. Invest. Dermatol. 132(1), 170-178 (2012).
94. Reifenberger J, Wolter M, Boström J et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 436(5), 487-493 (2000).
95. Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet. Cytogenet. 125(1), 21-26 (2001).
96. Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57(17), 3660-3663 (1997).
97. Furney SJ, Turajlic S, Fenwick K et al. Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res. 25(4), 488-492 (2012).
98. Nikolaev SI, Rimoldi D, Iseli C et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44(2), 133-139 (2012).
99. You MJ, Castrillon DH, Bastian BC et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl Acad. Sci. USA 99(3), 1455-1460 (2002).
100. Murisier F, Guichard S, Beermann F. A conserved transcriptional enhancer that specifies Tyrp1 expression to melanocytes. Dev. Biol. 298(2), 644-655 (2006).
101. Porter S, Larue L, Mintz B. Mosaicism of tyrosinase-locus transcription and chromatin structure in dark vs. light melanocyte clones of homozygous chinchilla-mottled mice. Dev. Genet. 12(6), 393-402 (1991).
102. Porter SD, Hu J, Gilks CB. Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. Dev. Genet. 25(1), 40-48 (1999).
103. Delmas V, Martinozzi S, Bourgeois Y, Holzenberger M, Larue L. Cre-mediated recombination in the skin melanocyte lineage. Genesis 36(2), 73-80 (2003).
104. Tonks ID, Nurcombe V, Paterson C et al. Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelialderived tissues. Genesis 37(3), 131-138 (2003).
105. Bosenberg M, Muthusamy V, Curley DP et al. Characterization of melanocyte-specif?ic inducible Cre recombinase transgenic mice. Genesis 44(5), 262-267 (2006).
106. Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis 44(1), 34-43 (2006).
107. Guyonneau L, Murisier F, Rossier A, Moulin A, Beermann F. Melanocytes and pigmentation are affected in dopachrome tautomerase knockout mice. Mol. Cell. Biol. 24(8), 3396-3403 (2004).
108. Inoue-Narita T, Hamada K, Sasaki T et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res. 68(14), 5760-5768 (2008).
109. Dankort D, Curley DP, Cartlidge RA et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41(5), 544-552 (2009).
110. Damsky WE, Curley DP, Santhanakrishnan M et al. Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20(6), 741-754 (2011).
111. Karreth FA, Tay Y, Perna D et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147(2), 382-395 (2011).
112. Nogueira C, Kim KH, Sung H et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29(47), 6222-6232 (2010).
113. Longvert C, Gros G, Beermann F, Marais R, Delmas V, Larue L. Murine cutaneous melanoma models. Importance of the genetic background. Ann. Pathol. 31(5 Suppl.), S70-S73 (2011).